Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 1999

View Archived Issues

Bayer describes new oxazolidinone antibacterials in recently issued patent

Dihydropyridines from Pfizer show excellent bradykinin-antagonist effects

New benzimidazoles useful in the treatment of diabetes and its complications under study at ADIR

9a-Azalides with potent antibacterial activity in development at Merck

Pharmacia & Upjohn describes new triazinic compounds with multiple pharmacological effects

AMPA receptor antagonists in the pipeline at Schering

Pharmacological characterization of fluodipine: a new selective bradycardic agent

New AIDS vaccine expected to begin clinical trials later this year

Ziagen introduced by Glaxo Wellcome as new HIV treatment option

Vanguard Medica and Elan seek regulatory approval of Miguard in the U.S.

Beneficial vascular effects of estrogen therapy in hypercholesterolemic postmenopausal women

NeuroSearch commences phase II clinical trials of potential antidepressant

Ilex Oncology adds Canadian trial site to intoplicine development

Phase I clinical trial commences in Germany for insomnia compound

IND for MRE-0470 approved by FDA

First NDA filing for Prevatac expected to be delayed

AxyS and Protein Design Labs enter drug discovery agreement

Nexell acquires most CellPro assets and forms new diagnostics division

Sonus and Abbott amend EchoGen agreements

Proteasome inhibitors show potential in inflammatory disorders

Coulter: Q4 and FY 1998 highlights

Titan completes private placement, updates R&D progress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...